EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Fibrocystic disease of the breast in premenopausal women histohormonal correlation and response to lhrh analog treatment



Fibrocystic disease of the breast in premenopausal women histohormonal correlation and response to lhrh analog treatment



American Journal of Obstetrics & Gynecology 164(5 PART 1): 1181-1189



Sixty-six patients with fibrocystic mastopathy were enrolled in the trial after being selected according to clinical, radioultrasonographic, and histologic criteria. No characteristic hormonal profile was noted in most patients (52%). Estrogen receptors or progesterone receptors, or both, were found in 57% of patients. Hormone receptor levels were correlated with atypical proliferative mastopathy (87.5%). Mastopathy was associated with a uterine fibroma or a fibromatous uterus in 73% of cases. All patients received intramuscular injections of a sustained delivery system (microcapsules) of luteinizing hormone releasing hormone agonist [D-Trp6]-LHRH, Ipsen-Biotech, Paris) for 3 to 6 months. In case of partial response at 3 months, an antiestrogen (tamoxifen, 40 mg/day, for estrogen receptor-predominant lesions) or a progestin (cyproterone acetate, 50 mg/day, for progesterone receptor-predominant lesions) was added to the luteinizing hormone releasing hormone agonist. A complete response was observed in more than half of the patients (n = 35, 53%) treated by [D-Trp6]-LHRH alone (n = 29) or associated with tamoxifen (n = 4) or cyproterone acetate (n = 2). A significant partial response was observed in 30 other patients (45%). Additionally, half of them received inhibitory drugs. The best responses were seen with cyst reformation (complete response, 100%) and fibrous block. Clinical responses to treatment with [D-Trp6]-LHRH alone were independent of hormone receptor status, but synergistic effects occurred with concomitant use of the corresponding inhibitory drugs. We conclude that chronic mastopathy, particularly when associated with uterine fibroma, can be successfully treated by luteinizing hormone releasing hormone analogs in premenopausal women.

(PDF emailed within 1 workday: $29.90)

Accession: 007349136

Download citation: RISBibTeXText



Related references

Fibrocystic disease of the breast in premenopausal women: histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment. American Journal of Obstetrics and Gynecology 164(5 Pt 1): 1181-1189, 1991

Treatment of fibrocystic disease of the breast with lhrh analog. International Journal of Gynecology & Obstetrics (ABSTR SUPPL): 125, 1991

Prolactin and thyrotropin response to trh in premenopausal women with fibrocystic disease of the breast. Hormone Research (Basel) 21(3): 137-144, 1985

Prolactin and thyrotropin response to thyrotropin-releasing hormone in premenopausal women with fibrocystic disease of the breast. Hormone Research 21(3): 137-144, 1985

Therapeutic potential of the lhrh agonist zoladex ici 118630 in the treatment of advanced breast cancer in premenopausal and postmenopausal women. Journal of Steroid Biochemistry 20(6 PART B): 1409, 1984

Preliminary endocrinological evaluation of a sustained release formulation of the lhrh agonist 6 tert butyl d serine 10 azaglycine lhrh in premenopausal women with advanced breast cancer. Journal of Endocrinology 111(2): 349-353, 1986

Response of fibrocystic disease to caffeine withdrawal and correlation of cyclic nucleotides with breast disease. American Journal of Obstetrics and Gynecology 135(1): 157-158, 1979

Breast tissue and breast duct fluid dhas concentrations in premenopausal mammary cancer and fibrocystic disease. Castagnetta, L , Et Al (Ed ) Annals Of The New York Academy Of Sciences, Vol 595 Steroid Formation, Degradation, And Action in Peripheral Tissues; First International Symposium, Taormina, Italy, March 14-18, 1989 Xiii+489p New York Academy Of Sciences: New York, New York, Usa Illus 467-472, 1990

Suppressive effect of an inhibitory LHRH analog on the gonadotropin response to LHRH in normal women. International Journal of Fertility 25(3): 190-192, 1980

Effect of pre treatment of long term ovariectomized rats with anti lhrh on the response of the pituitary gland in vitro to the analog of lhrh 6 tert butyl d serine des 10 glycine lhrh ethylamide buserelin. Acta Endocrinologica 104(3): 272-278, 1983

Evaluation of danazol treatment of women with fibrocystic disease of breast. Polski Tygodnik Lekarski 44(32-33): 771-773, 1989

Tamoxifen effects on treatment fibrocystic breast disease in women. Saudi Medical Journal 27(4): 565-566, 2006

Correlation between estrogen receptor levels and clinical response to ovariectomy in premenopausal women with advanced breast cancer. European Journal of Surgical Oncology 12(4): 343-346, 1986

Goserelin an lhrh agonist in the treatment of women with fibrocystic mastopathy a pilot study. Journal of Obstetrics & Gynaecology (Abingdon) 11(4): 272-276, 1991

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database of Systematic Reviews (): Cd004562-Cd004562, 2010